Li-Hua Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li-Hua Gong has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Fei-Yun Zheng
Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical College, Shangcai Village South, Ouhai District, Wenzhou, Zhejiang 325000, China
1 shared publicationHuan Wang
Department of Gynecology, The Third Affiliated Hospital of Sun-Yat Sen University, Guangzhou, Guangdong 510632, China
1 shared publicationJian-Ge Qiu
Department of Cell Biology and Institute of Biomedicine, College of Life Science and Technology, Jinan University, Room 708, The 2nd Engineer and Scientific Building, 601 Huangpu RoadWest, Guangzhou, Guangdong 510632, China
1 shared publication- Qiwei Jiang
Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication Shi-Shi Pan
Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical College, Shangcai Village South, Ouhai District, Wenzhou, Zhejiang 325000, China
1 shared publication- Wu-Ming Qin
Department of Cell Biology and Institute of Biomedicine, College of Life Science and Technology, Jinan University, Room 708, The 2nd Engineer and Scientific Building, 601 Huangpu RoadWest, Guangzhou, Guangdong 510632, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2014, 1-10
Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
Piperlongumine (PL), a natural alkaloid fromPiper longum L., possesses the highly selective and effective anticancer property. However, the effect of PL on ovarian cancer cells is still unknown. In this study, we firstly demonstrate that PL selectively inhibited cell growth of human ovarian cancer cells. Furthermore, PL notably induced cell apoptosis, G2/M phase arrest, and accumulation of the intracellular reactive oxidative species (ROS) in a dose- and time-dependent manner. Pretreatment with antioxidant N-acety-L-cysteine could totally reverse the PL-induced ROS accumulation and cell apoptosis. In addition, low dose of PL/cisplatin or paclitaxel combination therapies had a synergistic antigrowth effect on human ovarian cancer cells. Collectively, our study provides new therapeutic potential of PL on human ovarian cancer.
- 1 January 2014
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2014, 1-10
Open AccessPiperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
Piperlongumine (PL), a natural alkaloid fromPiper longum L., possesses the highly selective and effective anticancer property. However, the effect of PL on ovarian cancer cells is still unknown. In this study, we firstly demonstrate that PL selectively inhibited cell growth of human ovarian cancer cells. Furthermore, PL notably induced cell apoptosis, G2/M phase arrest, and accumulation of the intracellular reactive oxidative species (ROS) in a dose- and time-dependent manner. Pretreatment with antioxidant N-acety-L-cysteine could totally reverse the PL-induced ROS accumulation and cell apoptosis. In addition, low dose of PL/cisplatin or paclitaxel combination therapies had a synergistic antigrowth effect on human ovarian cancer cells. Collectively, our study provides new therapeutic potential of PL on human ovarian cancer.